These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32810338)

  • 1. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
    Kario K; Okada K; Murata M; Suzuki D; Yamagiwa K; Abe Y; Usui I; Tsuchiya N; Iwashita C; Harada N; Okawara Y; Ishibashi S; Hoshide S
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1585-1593. PubMed ID: 32810338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
    Chino Y; Kuwabara M; Hisatome I
    J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
    Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
    Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
    Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luseogliflozin for the treatment of type 2 diabetes.
    Seino Y
    Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.
    Bouchi R; Terashima M; Sasahara Y; Asakawa M; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Cardiovasc Diabetol; 2017 Mar; 16(1):32. PubMed ID: 28253918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
    Kameda R; Nomoto H; Cho KY; Kawata S; Omori K; Takeuchi J; Nagai S; Kurihara Y; Aoki S; Nakamura A; Atsumi T; Miyoshi H
    BMJ Open; 2020 Feb; 10(2):e034883. PubMed ID: 32034028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
    Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Nanba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
    J Am Heart Assoc; 2020 Aug; 9(16):e015103. PubMed ID: 32805185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
    Samukawa Y; Mutoh M; Chen S; Mizui N
    Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
    Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
    Bando S; Ichikawa R; Taguchi T; Fujimoto K; Motomiya T; Taguchi M; Takano K; Shichiri M; Miyatsuka T
    Endocr J; 2022 Jun; 69(6):681-687. PubMed ID: 35067495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
    Sasaki T; Sugawara M; Fukuda M
    J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
    Ejiri K; Miyoshi T; Nakamura K; Sakuragi S; Munemasa M; Namba S; Takaishi A; Ito H
    BMJ Open; 2019 Mar; 9(3):e026590. PubMed ID: 30928954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial.
    Seino H
    Diabetes Ther; 2021 Mar; 12(3):863-877. PubMed ID: 33594581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
    Kario K; Okada K; Kato M; Nishizawa M; Yoshida T; Asano T; Uchiyama K; Niijima Y; Katsuya T; Urata H; Osuga JI; Fujiwara T; Yamazaki S; Tomitani N; Kanegae H
    Circulation; 2019 Apr; 139(18):2089-2097. PubMed ID: 30586745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.